Tonix Pharmaceuticals Hld

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Faraday Future Intelligent Electric

HTG Molecular Diagnostics

Need help researching penny stocks to buy? Use these tips The post How to Conduct Due Diligence on Penny Stocks, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Conduct Due Diligence on Penny Stocks, 3 Tips

Today is a banner day for anyone who happened to hold Tonix Pharmaceuticals (NASDAQ: TNXP ) stock over the weekend. Early this morning, Tonix disclosed an exclusive license with a drug developer which could produce an entirely new approach to treating Covid-19.

Why Is Tonix Pharmaceuticals (TNXP) Stock Up 40% Today?

Immunocompromised Individuals, Including Organ Transplant Recipients, are at Increased Risk of Severe COVID-19 and Poor Clinical Outcomes

Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Humanized anti-SARS-CoV-2 Monoclonal Antibodies from Curia Global, Inc.

Hematopoietic Stem Cell Transplantation (HCT) from Unrelated Donors is a Component of the Treatment Protocol for Several Hematologic Malignancies

Tonix Pharmaceuticals Announces Collaboration with Boston Children's Hospital to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Graft-versus-Host Disease (GvHD) Following Hematopoietic Stem Cell Transplantation in Animals

Research Being Conducted in Collaboration with Scientists at Columbia University

Tonix Pharmaceuticals Announced Data from its Fully Human anti-SARS-CoV-2 Monoclonal Antibody Platform in an Oral Presentation at the World Antiviral Congress

CHATHAM, N.J., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that management will participate virtually in the A.G.P. Biotech Conference and host investor meetings. The conference is being held Wednesday, November 30, 2022 – Thursday, December 1, 2022.

Tonix Pharmaceuticals to Participate in the A.G.P. Biotech Conference

CHATHAM, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will deliver an oral presentation at the World Vaccine and Immunotherapy Congress 2022, which will be held in San Diego, Calif., November 28 - December 1, 2022. A copy of the Company's presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the World Vaccine and Immunotherapy Congress website here.

Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine and Immunotherapy Congress

CHATHAM, N.J., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will deliver an oral presentation at the World Antiviral Congress 2022, which will be held in San Diego, Calif., November 28 - December 1, 2022. A copy of the presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the World Antiviral Congress website here.

Tonix Pharmaceuticals Announces Oral Presentation at the World Antiviral Congress

CHATHAM, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced data describing the impact of oxytocin on isolated human sensory neurons, presented at Neuroscience 2022, the annual meeting of the Society for Neuroscience. A copy of the poster is available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.

Tonix Pharmaceuticals Announces Data from an in vitro Study of the Impact of Oxytocin on Human Neurons at Neuroscience 2022, the Annual Meeting of the Society for Neuroscience

CHATHAM, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced a poster presentation by an academic collaborator at Neuroscience 2022 by the Society for Neuroscience being held November 12-16, 2022, at the San Diego Convention Center in San Diego, Calif.

Tonix Pharmaceuticals Announces Poster Presentation at Neuroscience 2022 by the Society for Neuroscience

Five Potentially Pivotal Phase 2 or 3 Studies for CNS Programs Expected to be in the Clinic by First Quarter 2023

Tonix Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights

CHATHAM, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at BioFuture on Tuesday, November 8, 2022, at 11:00 a.m. ET, and host investor meetings. The conference is being held at the Lotte New York Palace in New York City.

Tonix Pharmaceuticals to Present at the 2022 BioFuture Conference

CHATHAM, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 1,400,000 shares of Series A convertible redeemable preferred stock and 100,000 shares of Series B convertible redeemable preferred stock. Each share of Series A and Series B preferred stock has a purchase price of $9.50, representing an original issue discount of 5% of the $10.00 stated value of each share. Each share of Series A and Series B preferred stock is convertible into shares of the Company's common stock at an initial conversion price of $1.00 per share. Shares of the Series A and Series B preferred stock are convertible at the option of the holder at any time following the Company's receipt of shareholder approval for an increase to the authorized shares of common stock of the Company from 150 million to 1 billion. The Company and the holders of the Series A and Series B preferred stock also entered into a registration rights agreement to register the resale of the shares of common stock issuable upon conversion of the Series A and Series B preferred stock. Total gross proceeds from the offerings, before deducting discounts, placement agent's fees and other estimated offering expenses, is $15 million.

Tonix Pharmaceuticals Announces Pricing of $15 Million Private Placement of Convertible Redeemable Preferred Stock

CHATHAM, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Wednesday, October 26, 2022, at 10:30 a.m. ET, and host investor meetings. The conference is being held at the Mandarin Oriental, New York in New York City.

Tonix Pharmaceuticals to Present at the 2022 ThinkEquity Conference

CHATHAM, N.J., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will participate in one-on-one meetings at the 2022 BIO-Europe Conference being held in Leipzig, Germany, October 24-26, 2022. The Company's presentation will be available to registered participants through the conference partnering site.

Tonix Pharmaceuticals to Participate in the 2022 BIO-Europe Conference

TNX-601 ER, Tianeptine Hemioxalate, is an Extended-Release Tablet for Once-a-Day Dosing

Tonix Pharmaceuticals Announces IND Clearance for TNX-601 ER as a Potential Treatment for Major Depressive Disorder

Approximately 40% of Long COVID Patients Experience Multi-Site Pain Similar to Overlapping Chronic Pain Syndromes Fibromyalgia and ME/CFS

Tonix Pharmaceuticals Presents Data from Retrospective Observational Database Study on the Incidence of Multi-Site Pain Symptoms in Long COVID Patients at IASP 2022 World Congress on Pain

TNX-1500 Treatment Prevents Organ Rejection and Preserves Function for Both Allograft and Xenograft Transplants in Animal Studies

Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Rejection in Allograft and Xenograft Transplantation in Animal Models at the International Congress of The Transplantation Society (TT

CHATHAM, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced three oral presentations by academic collaborators at the 29th International Congress of The Transplantation Society (TTS 2022) being held September 10-14, 2022 in Buenos Aires, Argentina, and virtually. Copies of the presentations will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference.

Tonix Pharmaceuticals Announces Oral Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) at the International Congress of The Transplantation Society (TTS 2022)

Results from Planned Interim Analysis Expected First Half 2023

Tonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVAIL Study of TNX-102 SL for the Treatment of Long COVID

Applied DNA Sciences

Chimerix

Geovax Labs

iShares Genomics Immunology and Healthcare ETF

SIGA Technologies

Monkeypox stocks, our topic for today, have had a mostly mixed performance so far in 2022. It is likely, however, that they could benefit from the similar tailwinds enjoyed by companies, such as Pfizer (NYSE: PFE ), BioNTech (NASDAQ: BNTX ), and Moderna (NASDAQ: MRNA ), which have developed the Covid-19 vaccines that have now become household names.

7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher

Phase 1 Study of TNX-801, a Vaccine in Development for the Prevention of Monkeypox and Smallpox, Expected to Initiate in First Half 2023 in Kenya; the U.S. has Declared Monkeypox a Public Health Emergency

Tonix Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights

Aethlon Medical

Chembio Diagnostics

E-Home Household Service Holdings Ltd

NanoViricides

10 monkeypox stocks and monkeypox penny stocks to watch The post 10 Top Monkeypox Stocks To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Monkeypox Stocks To Watch Right Now

Monkeypox penny stocks to watch this week. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 4 Monkeypox Stocks To Watch This Week

AMTD International Inc

MediaCo Holding Inc.

Here's what you need to know about buying penny stocks on August 2nd The post Best Penny Stocks to Watch Before Market Open on August 2nd  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Tonix Pharmaceuticals Hld Stock (TNXP)